1 Characterizing the blood stage antimalarial activity of pyronaridine in healthy

2 volunteers experimentally infected with *Plasmodium falciparum*

- 3
- 4 Bridget E. Barber^{1,2,5}, Rebecca Webster¹, Adam J. Potter¹, Stacey Llewellyn¹, Nischal Sahai²,
- 5 Indika Leelasena², Susan Mathison², Karsten Kuritz³, Julia Flynn⁴, Stephan Chalon⁴, Anne
- 6 Claire Marrast⁴, Nathalie Gobeau⁴, Joerg J. Moehrle^{4*}
- 7
- ¹QIMR Berghofer Medical Research Institute, Brisbane, Australia
- 9 ²University of the Sunshine Coast, Morayfield, Australia
- ³IntiQuan GmbH, Basel, Switzerland
- ⁴Medicines for Malaria Venture, Geneva, Switzerland
- ⁵Royal Brisbane and Women's Hospital, Brisbane, Australia

13

14 ***Corresponding author:** A/Prof. Joerg Moehrle. Medicines for Malaria Venture, Route de

15 Prés-Bois 20, 1215 Geneva 15, Switzerland. Email: moehrlej@mmv.org. Telephone: + 41 79

16 8234 666.

- 17
- 18 Keywords: *Plasmodium falciparum*, pyronaridine, blood stage, volunteer infection study,
- 19 antimalarial, pharmacokinetics, pharmacodynamics.
- 20 **Running title:** Antimalarial activity of pyronaridine.

21 ABSTRACT

22	Although pyronaridine has been used to successfully treat malaria for many years, its
23	antimalarial activity in humans has not been completely characterized. This volunteer
24	infection study aimed to determine the pharmacokinetic/pharmacodynamic (PK/PD)
25	relationship of pyronaridine in healthy malaria naïve adults. Volunteers were inoculated with
26	Plasmodium falciparum 3D7-infected erythrocytes on day 0 and different single oral doses of
27	pyronaridine were administered on day 8. Parasitemia, and concentrations of pyronaridine in
28	whole blood were measured and standard safety assessments performed. Curative artemether-
29	lumefantrine therapy was administered if parasite regrowth occurred, or on day 47±2.
30	Outcomes were parasite clearance kinetics, PK and PK/PD parameters from modelling. Ten
31	participants were inoculated and administered 360 mg (n=4), 540 mg (n=4), or 720 mg (n=1)
32	pyronaridine. One participant was withdrawn without receiving pyronaridine. Time to
33	maximum pyronaridine concentration after dosing was 1-2 hours and the elimination half-life
34	was 8-9 days. A parasite clearance half-life of approximately 5 hours was calculated for all
35	dose levels. Parasite regrowth occurred after dosing with 360 mg (4/4 participants) and 540
36	mg (2/4 participants). Key efficacy parameters of pyronaridine including the minimum
37	inhibitory concentration (MIC: 5.5 ng/mL) and minimum parasiticidal concentration that
38	leads to 90% of maximum effect (MPC90: 8 ng/mL) were derived from the final PK/PD
39	model. Adverse events considered related to pyronaridine were predominantly mild to
40	moderate gastrointestinal symptoms. There were no serious adverse events. Data obtained in
41	this study will support the use of pyronaridine in new antimalarial combination therapies by
42	informing partner drug selection and dosing considerations.

43 Abbreviations: AEs: adverse events; IBSM: induced blood stage malaria; PK/PD:

44 pharmacokinetic/pharmacodynamics; VIS: volunteer infection study.

45 **INTRODUCTION**

46 Malaria continues to be responsible for a large global health burden, with an estimated 247 47 million cases and 619,000 deaths in 2021 [1]. The emergence of artemisinin-resistant 48 *Plasmodium falciparum* in Southeast Asia [2], and more recently in East Africa [3], threatens 49 the utility of the current first line artemisinin combination therapies (ACTs) and progress 50 toward malaria eradication. The development of novel antimalarial therapies is an important 51 strategy to combat the spread of resistance and there are currently significant efforts to 52 progress several promising new antimalarial compounds through clinical development [4]. 53 However, the progress of a new compound from bench to bedside is typically a lengthy 54 process and additional strategies are required to control malaria in the nearer term. 55 Optimizing the use of existing non-artemisinin antimalarial drugs is one such strategy that 56 has potential to reduce malaria morbidity and mortality and slow the spread of antimalarial 57 resistance. 58 Pyronaridine is an antimalarial compound first developed in China in the 1970's and has been 59 shown to have potent activity towards blood-stage P. falciparum, including isolates resistant 60 to chloroquine, quinine, amodiaquine, pyrimethamine or mefloquine [5]. The antimalarial 61 activity of pyronaridine is thought to occur primarily due to inhibition of hemozoin 62 formation, which results in accumulation of toxic hematin in the parasite food vacuole [6]. 63 Pyronaridine has been used as a single agent for the treatment of malaria in China for over 30 64 years and was subsequently developed as a fixed-dose combination therapy with artesunate 65 (an artemisinin derivative) for the treatment of acute uncomplicated *P. falciparum* malaria 66 and blood stage *P. vivax* (Pyramax®: pyronaridine-artesunate). *Pyramax* is currently 67 registered in several countries in Africa and Asia, has received positive opinion through 68 article 58 by the European Medicines Agency [7], is on the World Health Organization

69 (WHO) Model Lists of Essential Medicines for adults and children, and is recommended by

70	the current WHO guidelines for malaria [8]. The recommended Pyramax dosing regimen for
71	patients \geq 65 kg is 720 mg pyronaridine/ 240 mg artesunate daily for three consecutive days.
72	Despite the fact that pyronaridine has been used to successfully treat malaria for many years,
73	either in monotherapy or in combination with other antimalarial drugs [5], its antimalarial
74	activity in humans has not been completely characterized. Determining the relationship
75	between pyronaridine pharmacokinetics (PK) and pharmacodynamic (PD) antimalarial
76	activity in humans would inform efforts to broaden its use in new combination therapies.
77	Combination therapies are the focus of antimalarial drug development to reduce the risk of
78	selecting for resistant mutants and to target multiple stages of the parasite lifecycle including
79	the transmissible gametocytes [9]. Further, using a combination of two or more drugs is
80	typically considered a prerequisite for achieving cure without the need for an extended dosing
81	regimen, which would pose compliance challenges. In the case of ACTs, the fast-acting
82	artemisinin component rapidly reduces the parasite burden, while a partner drug with a more
83	moderate rate of action but longer elimination half-life is relied upon to clear residual
84	parasites and prevent recrudescence. The rate of action of pyronaridine in clearing malaria
85	parasitaemia in humans is unclear; however clinical pharmacokinetic studies in malaria
86	patients have demonstrated that it has a relatively long elimination half-life of 13.2 days in
87	adults and 9.6 days in children [5] and thus may be able to offer extended protection from
88	recrudescence.
89	Volunteer infection studies (VIS) using the induced blood stage malaria (IBSM) model have

90 previously successfully characterized the PK/PD relationship of several experimental 91 antimalarial compounds as well as antimalarial drugs currently in use [10-13]. The IBSM 92 model involves intravenous inoculation of healthy malaria naïve adult participants with 93 blood-stage parasites and subsequent administration of the test antimalarial. Frequent blood 94 sampling is performed to measure parasitaemia and drug concentration kinetics over the

95	course of the study, thus providing data for PK/PD modelling analyses. Such VIS have been
96	shown to accurately predict the activity of investigational antimalarials administered as
97	monotherapy in studies in endemic populations [14, 15].
98	The primary objective of the current study was to determine the PK/PD relationship of
99	pyronaridine following administration in healthy adult participants using the P. falciparum
100	IBSM model. Data obtained in this study will support the use of pyronaridine in new
101	antimalarial combination therapies by informing partner drug selection and dosing
102	considerations.
103	METHODS
104	Study design and participants
105	This was an open label, randomized, clinical trial using the IBSM model. Healthy malaria
106	naïve males and females (non-pregnant, non-lactating) aged 18-55 years were eligible for
107	inclusion (Text S1). The study was conducted at the University of the Sunshine Coast
108	Clinical Trials Unit (Morayfield, Australia) and was registered on ClinicalTrials.gov
109	(NCT05287893). This study was approved by the QIMR Berghofer Human Research Ethics
110	Committee (P3800). All participants gave written informed consent.
111	Procedures
112	Participants were inoculated intravenously with approximately 2800 viable P. falciparum
113	3D7 infected erythrocytes on day 0. Parasitemia was monitored throughout the study by

- 114 quantitative PCR (qPCR) targeting the gene encoding *P. falciparum* 18S rRNA [16]. A single
- oral dose of pyronaridine in tablet form (Shin Poong Pharmaceutical Co., Ltd, Seoul, South
- 116 Korea) was administered on day 8 after an overnight fast. Participants were randomized to a
- 117 dose group on day 8. The randomization schedule was generated using SAS. No blinding was
- 118 performed.

119	Whole blood concentrations of pyronaridine were measured by liquid chromatography
120	tandem mass spectrometry using a validated method. Participants received a curative course
121	of artemether-lumefantrine (Riamet®, Novartis Pharmaceuticals) if asexual parasite regrowth
122	was detected (≥5,000 parasites/mL), or on day 47±2. The presence of female gametocytes,
123	male gametocytes and ring stage parasites in participants' blood samples was detected at
124	select time points using qRT-PCR targeting pfs25, pfMGET and SBP-1 parasite transcripts
125	respectively [17, 18]. The protocol specified that a single 45 mg dose of primaquine
126	(Primacin®, Boucher & Muir Pty Ltd) could be administered after artemether-lumefantrine
127	treatment (cohort 1) or any time after pyronaridine dosing (cohort 2) to clear gametocytemia.
128	Safety assessments, including monitoring of adverse events (AEs), vital signs, hematology
129	and biochemistry, physical examination, and electrocardiographs, were performed throughout
130	the study.

131 Outcomes and Statistical analysis

132 Analysis of parasite clearance kinetics following pyronaridine was performed in R statistical

package version 4.1.3 (2022-03-10). The parasite reduction ratio over a 48-hour period

134 (PRR₄₈) and parasite clearance half-life (PCt_{1/2}) were estimated using the slope of the optimal

fit for the log-linear relationship of the parasitemia decay [19]. Non-compartmental

136 pharmacokinetic analysis was performed using Phoenix version 8.3.

137 Pharmacokinetic (PK) and pharmacokinetic/pharmacodynamic (PK/PD) modelling and

simulations were conducted within R (3.6.3) combined to the IQRtools package (1.9.0) and

139 Monolix (MLX2019R1). PK/PD analyses were performed using non-linear mixed effects

- 140 models. A population PK model was developed to obtain individual PK parameter estimates
- 141 that adequately described the observed individual PK profiles. Model selection was based on
- the Bayesian Information Criterion (BIC), precision of parameter estimates, goodness of fit

143	and visual evaluation of the individual blood profiles. The PK/PD model was then built using
144	the individual PK parameter estimates as regression parameters. Parasitaemia data were log
145	transformed and observations below the lower limit of quantification were censored.
146	Additionally, data points where gametocytes were estimated to exceed 10% of the total
147	parasitaemia count were removed from the data set since only the asexual parasites were of
148	interest for the PD model and the count of gametocytes is not precise enough to back-
149	calculate the number of asexual parasites from the number of total parasites. Precision of
150	parameter estimates, visual evaluation of the individual parasitemia profiles and goodness of
151	fit plots ensured that the data were adequately described by the final PK/PD model.
152	Key efficacy parameters including the concentration that leads to 50% of maximum effect
153	(EC ₅₀), maximum effect (E_{max}), parasite reduction rate over 48 hours (PRR ₄₈), parasite
154	elimination half-life, minimum inhibitory concentration (MIC), and minimum parasiticidal
155	concentration (concentration that leads to 90% of maximum effect) (MPC $_{90}$) were derived
156	from the final PK/PD model.

157 **RESULTS**

158 **Participants**

159 The study was conducted from 04 April 2022 to 26 September 2022. Ten participants were 160 enrolled across two cohorts and intravenously inoculated with P. falciparum on day 0 (Figure 1). Participants were healthy malaria-naïve males (n=7) or females (n=3) aged 19 to 52 years 161 162 (Table 1). One participant enrolled in cohort 1 tested positive for COVID-19 on day 6 and 163 therefore was not dosed with pyronaridine. This participant instead received immediate 164 definitive antimalarial treatment with artemether-lumefantrine. The remaining 9 participants were randomized to a pyronaridine dose group on day 8 (360 mg, n=4; 540 mg, n=4; or 720 165 166 mg, n=1). Doses were selected to optimally characterize the PK/PD relationship. All 9

167 randomized participants received the allocated dose of pyronaridine, completed the study and

168 were included in the analysis of study endpoints.

169 Parasitemia and drug exposure

170 The progression of parasitemia following intravenous inoculation was consistent between

171 participants up to day 8, when a single dose of pyronaridine was administered (Figure 2).

172 Dose-related increases in pyronaridine exposure (maximum concentration $[C_{max}]$ and area

under the concentration-time curve from time 0 to the last measured time point $[AUC_{0-last}]$)

174 were observed across the dose range (Table 3). Absorption was rapid, with time to maximum

175 concentration (t_{max}) approximately 1-2 h, while a relatively long elimination half-life ($t_{1/2}$) of

approximately 8-9 days was observed.

177 An initial reduction in parasitemia occurred in all participants following pyronaridine dosing,

178 with a parasite clearance half-life of approximately 5 hours for each dose group (Table 2).

Asexual parasite regrowth (differentiated from gametocytemia by qRT-PCR targeting

parasite lifecycle specific transcripts; Figure S1) occurred in all 4 participants dosed with 360

181 mg (6-20 days post-dose) and in two participants dosed with 540 mg pyronaridine (10-13

182 days post-dose). Asexual parasite regrowth was not observed in the other two participants

dosed with 540 mg up to day 48 when definitive antimalarial treatment with artemether-

184 lumefantrine was initiated. The participant dosed with 720 mg pyronaridine tested positive

for COVID-19 on day 24 (16 days post-dose) and thus received early definitive antimalarial

treatment with artemether-lumefantrine on the same day. Asexual parasite regrowth was not

187 observed in this participant at the time of treatment initiation.

188 Female and male gametocytes were detected in all participants after pyronaridine dosing

189 (Figure S1). In cohort 1, a single dose of primaquine was administered to 4 participants after

190 artemether-lumefantrine treatment to ensure the participants were free of gametocytes at the

191 end of study (Figure 1). Given the relatively high level of gametocytemia observed in cohort 192 1, the study protocol was amended for cohort 2 to permit primaguine administration at any 193 time after pyronaridine dosing. It was anticipated that earlier primaquine dosing would 194 reduce the confounding effect of gametocytemia on the PK/PD analysis. Three of the four 195 participants in cohort 2 were administered a single dose of primaguine prior to artemether-196 lumefantrine treatment (7-9 days after pyronaridine dosing). Rapid asexual parasite regrowth 197 occurred in the fourth participant (7 days after pyronaridine dosing) obviating the need for 198 primaquine dosing before artemether-lumefantrine treatment (Figure 1). 199 Pharmacokinetic/Pharmacodynamic analysis

200 The PK of pyronaridine was described by a two-compartment model with zero-order

absorption, linear elimination, and an additive and proportional residual error model (Table

S1). Body weight at baseline was included in the structural model as a covariate using an

allometric function with exponents fixed to 0.75 for clearance parameters and 1 for volume

204 parameters. The individual observed pyronaridine concentrations were well described by the

205 model (Figure S2). The estimated individual PK parameters were consecutively used in the

206 PK/PD analysis of pyronaridine.

207 The relationship between pyronaridine blood concentrations and parasite killing was

described by an E_{max} PK/PD model (Table S2). This model assumes an exponential growth of

209 the parasites and a direct effect of concentrations on the rate of parasite killing/clearance.

210 Population parameters were well estimated with a residual standard error (RSE) below 12%.

211 RSE as well as shrinkage were below 30% for the estimated inter-individual variability. The

212 individual observed parasitaemia profiles were well described by the model (Figure S3). Key

efficacy parameters for pyronaridine derived from the final PK/PD model are presented in

214 Table 4.

215 Safety and tolerability

216 A total of 139 AEs were reported for all 10 enrolled participants (Table 5), with 73 of these AEs being mild to moderate (grade 1 to 2) signs and symptoms of malaria (Table S4). There 217 218 were no serious adverse events or adverse events with severity of grade 3 or higher. There 219 were 14 AEs considered related to pyronaridine (Table S3), with gastrointestinal symptoms 220 (abdominal pain, dyspepsia, gastroesophageal reflux, nausea, vomiting) the most frequent 221 type of AE reported. Other AEs considered related to pyronaridine were headache, malaise, 222 decreased appetite, and decreased hemoglobin. The event of decreased hemoglobin occurred 223 in one male participant dosed with 360 mg pyronaridine, with a maximum decrease from 224 baseline (pre-malaria challenge) of 30 g/L recorded 14 days after pyronaridine dosing. The 225 participant's hemoglobin level normalized spontaneously prior to the end of study visit. In 226 addition to being considered potentially related to pyronaridine, the event was also 227 considered potentially related to the malaria challenge and to blood sampling during the 228 study. There were no clinically relevant trends in safety laboratory parameters over the course 229 of the study, including liver function tests.

230 DISCUSSION

231 The primary objective of this study was to characterize the antimalarial activity of

232 pyronaridine by assessing the PK/PD relationship in malaria naïve adults using the *P*.

233 falciparum IBSM model. Results confirmed that pyronaridine exhibits potent activity against

blood-stage *P. falciparum*. The pyronaridine doses tested in this study (360 mg, 540 mg and

235 720 mg) all resulted in initial rapid parasite clearance, with a parasite clearance half-life of

approximately 5 hours. There was no obvious difference in the rate of parasite clearance

- 237 between dose levels, although this study was not powered to detect such differences. The
- 238 parasite clearance rate characterized for pyronaridine is similar to that previously
- characterized for 10 mg/kg mefloquine (clearance half-life 6.2 hours) [12] and 640 mg

piperaquine (clearance half-life 5.2 hours) [20] using the *P. falciparum* IBSM model.

However, parasite clearance was slower than previously observed with 2 mg/kg oral

artesunate (clearance half-life 3.2 hours) [21].

243 The PK profile of pyronaridine observed in this study is somewhat different to the PK of

- 244 pyronaridine previously characterized in healthy adult volunteers and adult malaria patients
- administered the pyronaridine-artesunate combination. The elimination half-life was
- estimated to be 190-233 h (approximately 8-9 days) across the dose range in the current study
- as compared with 11.3 days (healthy volunteers) and 13.2 days (malaria patients) in

individuals receiving combination therapy [5]. Differences in the populations used for

analysis, and potential PK interactions between pyronaridine and artesunate, may be factors

contributing to the different PK profiles observed. However, the small sample size of the

251 current study in comparison with previous PK studies involving much larger sample sizes

252 means it is not possible to draw definitive conclusions with respect to differences in PK

253 profiles. Nevertheless, any potential differences in PK are not entirely relevant with respect to

254 determining the PK/PD relationship of pyronaridine since the PK and PD measurements

come from the same participants.

256 There were no safety concerns associated with single dose pyronaridine administration in this

study, with mild to moderate gastrointestinal symptoms the most frequent adverse events

258 observed. The good safety and tolerability profile of pyronaridine has been well established

in several clinical trials involving both monotherapy and combination antimalarial therapy [5,

260 22, 23]. Additionally, the malaria-related adverse events observed were consistent with

261 previous malaria volunteer infection studies.

262 A PK/PD model of pyronaridine was successfully developed in this study, enabling

estimation of key efficacy parameters. It is anticipated that this model will be valuable in

264	future efforts to expand the use of pyronaridine in new antimalarial combination therapies by
265	informing partner drug selection and dosing considerations. At the time of writing, a phase 2a
266	proof of concept study assessing the safety, efficacy, and PK of pyronaridine in combination
267	with a new antimalarial candidate (M5717) in patients with acute uncomplicated P .
268	falciparum malaria had begun recruiting (clinicaltrials.gov ID: NCT05689047). This study
269	was initiated following a preclinical study of the combination <i>in vitro</i> and in the <i>P</i> .
270	falciparum severe combined immunodeficient (SCID) mouse model [24]. The preclinical
271	study indicated that the compounds had additive parasitological properties and that
272	pyronaridine was able to suppress the selection of M5717-resistant parasites [24]. The fact
273	that M5717 also appears to be active against transmissible gametocytes [25] likely adds to its
274	suitability as a partner drug to pyronaridine given the high level of gametocytemia observed
275	following administration of pyronaridine in the current study. We have previously conducted
276	a VIS to characterize the antimalarial activity of M5717 using the IBSM model [26]. Thus,
277	clinical PK/PD data is now available for both M5717 and pyronaridine, which will be
278	valuable in the development of this antimalarial combination by informing dosing strategies.
279	A combination VIS may also be worthy of consideration to characterize the PK/PD
280	interaction of the drugs in vivo. Investigations are underway to identify other antimalarials
281	that may represent good partner drugs to pyronaridine in a new combination therapy.

282 FUNDING

This study was funded by a grant from the Bill and Melinda Gates Foundation (INV-007155)awarded to Medicines for Malaria Venture (MMV).

285 CONFLICTS OF INTEREST

286	BEB declares	receipt of	f funding	from	Medicines	for Malaria	Venture	(MMV)) to 1	perform th	e
								(,	,		

- study. JJM, ACM, JF, and NG are employees of MMV. ACM declares holding shares in
- 288 Novartis, Alcon and Idorsia. All other authors declare no conflicts of interest.

289 ACKNOWLEWDGEMENTS

- 290 We thank all the volunteers who participated in the study, the University of the Sunshine
- 291 Coast Clinical Trials Unit, Southern Star Research, Shin Poong Pharmaceutical for providing
- 292 pyronaridine, the Queensland Paediatric Infectious Diseases laboratory for qPCR analysis,
- 293 Swiss BioQuant for the measurement of pyronaridine concentrations, Jeremy Gower and
- Hayley Mitchell from the QIMR Berghofer Medical Research Institute for preparation of the
- 295 malaria challenge inoculum, and Hanu Ramachandruni and Alice Neequaye from MMV.

296

297 **REFERENCES**

- 298 1. World Health Organization. World Malaria Report 2022. Geneva.
- 299 2. Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in

300 Plasmodium falciparum malaria. N Engl J Med **2014**; 371(5): 411-23.

- 301 3. Balikagala B, Fukuda N, Ikeda M, et al. Evidence of Artemisinin-Resistant Malaria in
 302 Africa. N Engl J Med 2021; 385(13): 1163-71.
- Hooft van Huijsduijnen R, Wells TN. The antimalarial pipeline. Curr Opin Pharmacol
 2018; 42: 1-6.
- S. Croft SL, Duparc S, Arbe-Barnes SJ, et al. Review of pyronaridine anti-malarial
 properties and product characteristics. Malaria journal 2012; 11: 270.
- Bailly C. Pyronaridine: An update of its pharmacological activities and mechanisms
 of action. Biopolymers 2021; 112(4): e23398.

309	7.	Agency EM. Pyramax: Opinion on medicine for use outside EU. Available at:
310		https://www.ema.europa.eu/en/opinion-medicine-use-outside-EU/human/pyramax.
311		Accessed 28 August 2023.
312	8.	WHO Guidelines for malaria, 14 March 2023. Geneva: World Health Organization,
313		2023.
314	9.	Burrows JN, Duparc S, Gutteridge WE, et al. New developments in anti-malarial
315		target candidate and product profiles. Malaria journal 2017 ; 16(1): 26.
316	10.	Barber BE, Abd-Rahman AN, Webster R, et al. Characterizing the blood stage
317		antimalarial activity of tafenoquine in healthy volunteers experimentally infected with
318		Plasmodium falciparum. Clin Infect Dis 2023.
319	11.	Barber BE, Fernandez M, Patel HB, et al. Safety, pharmacokinetics, and antimalarial
320		activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised,
321		placebo-controlled, double-blind, single ascending dose study, pilot food-effect study,
322		and volunteer infection study. The Lancet Infectious diseases 2022; 22(6): 879-90.
323	12.	McCarthy JS, Lotharius J, Ruckle T, et al. Safety, tolerability, pharmacokinetics, and
324		activity of the novel long-acting antimalarial DSM265: a two-part first-in-human
325		phase 1a/1b randomised study. The Lancet Infectious diseases 2017 ; 17(6): 626-35.
326	13.	McCarthy JS, Ruckle T, Djeriou E, et al. A Phase II pilot trial to evaluate safety and
327		efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage
328		malaria infection study. Malaria journal 2016 ; 15: 469.
329	14.	Phyo AP, Jittamala P, Nosten FH, et al. Antimalarial activity of artefenomel (OZ439),
330		a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum
331		and Plasmodium vivax malaria: an open-label phase 2 trial. The Lancet Infectious
332		diseases 2016 ; 16(1): 61-9.

333	15.	Llanos-Cuentas A, Casapia M, Chuquiyauri R, et al. Antimalarial activity of single-
334		dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in
335		patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria
336		infection: a proof-of-concept, open-label, phase 2a study. The Lancet Infectious
337		diseases 2018 ; 18(8): 874-83.
338	16.	Rockett RJ, Tozer SJ, Peatey C, et al. A real-time, quantitative PCR method using
339		hydrolysis probes for the monitoring of Plasmodium falciparum load in
340		experimentally infected human volunteers. Malaria journal 2011; 10: 48.
341	17.	Wang CYT, Ballard E, Llewellyn S, et al. Assays for quantification of male and
342		female gametocytes in human blood by qRT-PCR in the absence of pure sex-specific
343		gametocyte standards. Malaria journal 2020 ; 19(1): 218.
344	18.	Tadesse FG, Lanke K, Nebie I, et al. Molecular Markers for Sensitive Detection of
345		Plasmodium falciparum Asexual Stage Parasites and their Application in a Malaria
346		Clinical Trial. Am J Trop Med Hyg 2017 ; 97(1): 188-98.
347	19.	Marquart L, Baker M, O'Rourke P, McCarthy JS. Evaluating the pharmacodynamic
348		effect of antimalarial drugs in clinical trials by quantitative PCR. Antimicrobial agents
349		and chemotherapy 2015 ; 59(7): 4249-59.
350	20.	Pasay CJ, Rockett R, Sekuloski S, et al. Piperaquine Monotherapy of Drug-
351		Susceptible Plasmodium falciparum Infection Results in Rapid Clearance of
352		Parasitemia but Is Followed by the Appearance of Gametocytemia. The Journal of
353		infectious diseases 2016 ; 214(1): 105-13.
354	21.	Watts RE, Odedra A, Marquart L, et al. Safety and parasite clearance of artemisinin-
355		resistant Plasmodium falciparum infection: A pilot and a randomised volunteer
356		infection study in Australia. PLoS Med 2020; 17(8): e1003203.

357	22.	Tona Lutete G, Mombo-Ngoma G, Assi SB, et al. Pyronaridine-artesunate real-world
358		safety, tolerability, and effectiveness in malaria patients in 5 African countries: A
359		single-arm, open-label, cohort event monitoring study. PLoS Med 2021; 18(6):
360		e1003669.
361	23.	West African Network for Clinical Trials of Antimalarial D. Pyronaridine-artesunate
362		or dihydroartemisinin-piperaquine versus current first-line therapies for repeated
363		treatment of uncomplicated malaria: a randomised, multicentre, open-label,
364		longitudinal, controlled, phase 3b/4 trial. Lancet (London, England) 2018;
365		391(10128): 1378-90.
366	24.	Rottmann M, Jonat B, Gumpp C, et al. Preclinical Antimalarial Combination Study of
367		M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a
368		Hemozoin Formation Inhibitor. Antimicrobial agents and chemotherapy 2020; 64(4).
369	25.	Baragana B, Hallyburton I, Lee MC, et al. A novel multiple-stage antimalarial agent
370		that inhibits protein synthesis. Nature 2015; 522(7556): 315-20.
371	26.	McCarthy JS, Yalkinoglu O, Odedra A, et al. Safety, pharmacokinetics, and
372		antimalarial activity of the novel plasmodium eukaryotic translation elongation factor
373		2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind,
374		single ascending dose study and volunteer infection study. The Lancet Infectious
375		diseases 2021 ; 21(12): 1713-24.
376	27.	Wang CYT, Ballard EL, Pava Z, et al. Analytical validation of a real-time hydrolysis
377		probe PCR assay for quantifying Plasmodium falciparum parasites in experimentally
378		infected human adults. Malaria journal 2021; 20(1): 181.
379		

381 **TABLES**

Table 1. Demographic and baseline characteristics of participants.

		Pyronaridine 360 mg	Pyronaridine 540 mg	Pyronaridine 720 mg	Total
		(N=4)	(N=4)	(N=1)	(N=10*)
Sex [n (%)]	Female	0 (0)	1 (25)	1 (100)	3 (30)
	Male	4 (100)	3 (75)	0 (0)	7 (70)
Race [n (%)]	White	2 (50)	4 (100)	1 (100)	8 (80)
	Asian	1 (25)	0 (0)	0 (0)	1 (10)
	Other	1 (25)	0 (0)	0 (0)	1 (10)
Age [years]	Mean (range)	30.8 (20-37)	36 (19-52)	19 (19-19)	32.8 (19-52)
Body weight [kg]	Mean (range)	77.6 (68.7-81.9)	79.1 (57.5-104)	87.9 (87.9-87.9)	78.3 (57.5-104)
Body mass index [kg/m ²]	Mean (range)	25.5 (23-29)	25.8 (19-30)	25.0 (25-25)	25.4 (19-30)

383 *Includes one participant who was inoculated with malaria but was withdrawn from the study without being dosed with pyronaridine.

Table 2. Parasite clearance parameters following single dose pyronaridine administration to healthy volunteers with induced *P*.

385 *falciparum* parasitemia.

	Pyronaridine 360 mg	Pyronaridine 540 mg	Pyronaridine 720 mg
	(N=4)	(N=4)	(N=1)
Log ₁₀ PRR ₄₈ (95% CI)	2.58 (2.43 - 2.74)	2.53 (2.37 - 2.68)	2.85 (2.65 - 3.06)
PCt _{1/2} [h (95% CI)]	5.59 (5.28 - 5.94)	5.71 (5.38 - 6.09)	5.06 (4.72 - 5.46)
Parasite regrowth incidence [n (%)]	4 (100)	2 (50)	0 (0)

386 $Log_{10}PRR_{48}$: logarithm to base 10 of the parasite reduction ratio over a 48-hour period; $PCt_{1/2}$: parasite clearance half-life.

 387
 Table 3. Pyronaridine venous whole blood non-compartmental pharmacokinetic parameters associated with single dose administration

388 to healthy volunteers with induced *P. falciparum* parasitemia.

	Pyronaridine 360 mg	Pyronaridine 540 mg	Pyronaridine 720 mg	
	(N=4)	(N=4)	(N=1)	
C _{max} (ng/mL)	154.2 (43.0)	250.6 (23.4)	320.0	
t _{max} (h)	1.5 (1.0-2.0)	2.0 (1.0-2.0)	1.0	
AUC _{0-last} (h×ng/mL)	2452.5 (45.6)	5202.4 (47.7)	8776.1	
t _{1/2} (h)	233.0 (16.2)	210.5 (11.0)	189.8	
CL/F (L/h)	123.6 (40.5)	95.2 (41.7)	79.3	
Vz/F (L)	41533 (43.9)	28921 (50.9)	21711	

389 Data for 360 mg and 540 mg groups are geometric means (coefficient of variation [%]) except t_{max} which is median (range). Summary statistics were not calculated for the

390 720 mg group because N=1. C_{max} : maximum observed concentration; t_{max} : time to reach the maximum observed concentration; AUC_{0-last}: area under the concentration-time

391 curve from time 0 (dosing) to the last sampling time at which the concentration is at or above the lower limit of quantification; t_{1/2}: apparent terminal half-life; CL/F: apparent

total clearance; Vz/F: apparent volume of distribution.

Parameter	Median [95% uncertainty interval]*		
EC ₅₀ (ng/mL)	5.7 [4.6, 7.3]		
E _{max} (1/h)	0.2 [0.19, 0.22]		
PRR ₄₈	2.4 [2.1, 2.7]		
Parasite elimination half-life (h)	6 [5.3, 6.8]		
MIC (ng/mL)	5.5 [4.3, 6.9]		
MPC ₉₀ (ng/mL)	8 [6.4, 10]		

Table 4. Key efficacy parameters for pyronaridine derived from the final PK/PD model.

394 *Results are based on 500 samples from the estimates' uncertainty distribution. EC₅₀: concentration that leads to 50% of maximum effect; E_{max}: maximum effect; PRR₄₈:

395 parasite reduction rate over 48 hours; MIC: Minimum inhibitory concentration; MPC₉₀: minimum parasiticidal concentration (concentration that leads to 90% of maximum

396 effect).

397

398

399

400 Table 5. Summary of adverse events.

AE category ^a	Pyronaridine 360 mg	Pyronaridine 540 mg	Pyronaridine 720 mg	Total
	(N=4)	(N=4)	(N=1)	(N=10*)
	Number of participants with at least one AE (%); total number of AEs			
Any AE	4 (100); 56	4 (100); 45	1 (100); 23	10 (100); 139
AE related to malaria	4 (100); 31	4 (100); 23	1 (100); 12	10 (100); 73
AE related to pyronaridine ^b	2 (50); 7	3 (75); 7	0 (0); 0	5 (50); 14
Grade 2 ^c AE	4 (100); 7	3 (75); 7	1 (100); 4	9 (90); 20
Grade 2 ^c AE related to malaria	2 (50); 3	3 (75); 7	1 (100); 2	7 (70); 13
Grade 2 ^c AE related to pyronaridine	1 (25); 1	1 (25); 3	0 (0); 0	2 (20); 4

401 *Includes one participant who was inoculated with malaria but was withdrawn from the study without being dosed with pyronaridine.

402 ^aAdverse events (AEs) were recorded from administration of the malaria challenge agent until the end of the study. The investigator assessed the relatedness of all adverse

- 403 events to malaria and pyronaridine (related or unrelated). Adverse events may have been considered related to more than one study intervention. None of the adverse events
- 404 met the pre-defined criteria for a Serious Adverse Event. ^bAdverse events related to pyronaridine are specified in Table S5. ^cThe medical assessment of adverse event
- 405 severity was recorded in accordance with the Common Terminology Criteria for Adverse Events v5.0, published 27 November 2017 (mild=grade 1; moderate=grade 2;
- 406 severe=grade 3; potentially life-threatening=grade 4; death related to AE= grade 5). No grade 3, grade 4 or grade 5 adverse events were recorded.

407 FIGURES



408

410 challenged with blood stage *P. falciparum*. Participants were randomized within each cohort

```
to a pyronaridine dose group on the day of dosing (8 days post-challenge). One participant
```

412 was withdrawn from the study after inoculation with malaria but prior to scheduled dosing

413 with pyronaridine. This participant was excluded from analysis of study endpoints.

- 414
- 415
- 416

Figure 1. Trial profile. Eligible participants were enrolled in one of two cohorts and







432 Figure 3. Individual participant whole blood pyronaridine concentration-time profiles.

Participants were administered a single oral dose of 360 mg (n=4), 540 mg (n=4), or 720 mg
(n=1) pyronaridine (PYR) 8 days following challenge with blood-stage *P. falciparum*. Whole
blood pyronaridine concentration was measured using liquid chromatography-tandem mass
spectrometry.

445 SUPPLEMENTARY MATERIAL

446	•	Figure S1. Individual participant parasite lifecycle stage results.
447	٠	Table S1. Population parameter estimates of the final pharmacokinetic model of
448		pyronaridine.
449	•	Figure S2. Individual fit plots from the pharmacokinetic model of pyronaridine.
450	•	Table S2. Population estimates of the final pharmacokinetic/pharmacodynamic model
451		of pyronaridine.
452	•	Figure S3. Individual fit plots from the pharmacokinetic/pharmacodynamic model of
453		pyronaridine.
454	•	Table S3. Incidence of adverse events related to pyronaridine.
455	•	Table S4. Incidence of adverse events related to malaria.
456	٠	Text S1. Participant eligibility criteria.